A Future for CD3 Antibodies in Immunotherapy of Type 1 Diabetes

Diabetologia - Germany
doi 10.1007/s00125-018-4808-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Human Trials and a Look Into the Future

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2009English

The Future of Care for Type 1 Diabetes

CMAJ
Medicine
2013English

Approaches in Immunotherapy, Regenerative Medicine, and Bioengineering for Type 1 Diabetes

Frontiers in Immunology
AllergyImmunology
2018English

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

EBV Infection and Anti-Cd3 Treatment for Type 1 Diabetes: Bad Cop, Good Cop?

Expert Review of Clinical Immunology
AllergyImmunology
2013English

Functional Comparison of Single-Chain and Two-Chain Anti-Cd3-Based Bispecific Antibodies in Gene Immunotherapy Applications

OncoImmunology
OncologyAllergyImmunology
2014English

TCRαβ/CD3 Disruption Enables CD3-specific Antileukemic T Cell Immunotherapy

JCI insight
Medicine
2018English

A Case of Fulminant Type 1 Diabetes With Transiently Positive Anti-Gad Antibodies

Endocrine Journal
EndocrinologyMetabolismDiabetes
2003English

A Type 1 Diabetes Technology Pathway: Consensus Statement for the Use of Technology in Type 1 Diabetes

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy